Long-Acting Growth Hormones to Account for More than 90% of Market Share across US, Germany, and Japan by 2030: Report

Rapid uptake of long-acting growth hormones (GH) is set to shake up the growth hormone deficiency (GHD) space in the three major markets (3MM): the US, Germany, and Japan. These therapies are projected to capture more than 90% of market share in this region by 2030 due to their potential to improve patient convenience and compliance, says GlobalData, a data and analytics company.

According to GlobalData’s recent report, ‘Growth Hormone Deficiency: Opportunity Assessment and Forecast to 2030’, usage of short-acting GHs will markedly decrease over the forecast period as almost all patients switch to treatment with long-acting GHs. These therapies only require patients to self-inject once per week, as compared to short-acting GHs, which require daily injections. 

Fiona Chisholm, pharma analyst at GlobalData says: “Short-acting GHs have remained the standard of care in GHD for decades. However, the need for daily injections is associated with poor treatment compliance and, in turn, leads to suboptimal therapeutic outcomes. By dramatically reducing injection burden for patients, long-acting GHs may improve compliance considerably.”

GlobalData’s report highlights four long-acting GHs that are projected to enter the market by 2030: Novo Nordisk’s Sogroya (somapacitan-beco), Ascendis Pharma’s TransCon hGH (lonapegsomatropin), Pfizer and OPKO Biologics’ somatrogon, and Hanmi Pharmaceuticals’ efpegsomatropin. TransCon hGH is expected to emerge as the market leader, accounting for approximately 47% of all long-acting GH sales by 2030.

“TransCon hGH is likely to perform well commercially due to its innovative design, which releases unmodified GH, and its strong efficacy profile,” Chisholm says. “Additionally, while Sogroya recently gained marketing authorization in the US, EU, and Japan for adult GHD, TransCon hGH will benefit from being the first long-acting GH to be approved in the more lucrative pediatric segment.”

Across the 3MM, the GHD market was valued at $1.08bn in 2020, approximately 71% of which was attributable to US sales. The market is projected to grow at a compound annual growth rate of 3.84% to reach $1.57bn by 2030.

Chisholm adds: “Uptake of long-acting GHs represents the main driver of growth over the forecast period. These drugs are expected to be priced at a premium to the currently marketed products due to their superior dosing regimens.”